38 results match your criteria: "Canada P.J.D.; and the Population Health Research Institute[Affiliation]"
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis.
N Engl J Med
July 2018
From Assistance Publique-Hôpitaux de Paris (APHP), National Reference Center for Familial Amyloidotic Polyneuropathy, Centre Hospitalier Universitaire (CHU) Bicêtre, INSERM Unité 1195, Université Paris-Sud, Le Kremlin-Bicêtre (D.A.), the Department of Neuromuscular Disorders and ALS, Hôpital de la Timone, Marseille (S.A.), and the Department of Neurology, Amyloid Network, CHU Henri Mondor-APHP, Créteil (V.P.-B.) - all in France; the National Institute of Medical Sciences and Nutrition-Salvador Zubiran, Mexico City (A.G.-D.); the Department of Clinical Research, eStudySite, San Diego, CA (W.D.O.); the Department of Neurology, National Taiwan University Hospital (C.-C.Y.), and the Department of Neurology, Taipei Veterans General Hospital (K.-P.L.), Taipei, Taiwan; Kumamoto University Hospital, Kumamoto (M.U.), and the Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, Matsumoto (Y.S.) - both in Japan; the Department of Cardiology, University of Heidelberg, Heidelberg (A.V.K.), and Medizinische Klinik B für Gastroenterologie und Hepatologie, Universitätsklinikum Münster, Münster (H.H.S.) - both in Germany; University Multiprofile Hospital for Active Treatment, Sofia, Bulgaria (I.T.); Hospital de Santo António, Centro Hospitalar do Porto, Porto, Portugal (T.C.); the Amyloidosis Center, Department of Medicine, Boston Medical Center (J.L.B.), and Harvard Medical School (S.D.S.), Boston; the Department of Clinical and Experimental Medicine, University Hospital of Messina, Messina, Italy (G.V.); the Departments of Neurology and Medicine, Vancouver General Hospital, Vancouver, BC, Canada (M.M.M.); the Department of Nephrology, Hospital Clinic, Barcelona (J.M.C.), and the Balearic Islands Health Research Institute and Hospital Son Llatzer, Palma de Mallorca (J.B.) - all in Spain; the Department of Neurology, Columbia University, College of Physicians and Surgeons, New York (T.H.B.); Samsung Medical Center, Sungkyunkwan University School of Medicine (B.J.K.), and the the Department of Neurology, Konkuk University Medical Center (J.O.), Seoul, South Korea; the Department of Neurology, Istanbul University, Istanbul, Turkey (Y.P.); the Division of Medicine, University College London, London (P.N.H.); Johns Hopkins Bayview Medical Center, Baltimore (M.P.); the Department of Neurology, Mayo Clinic, Rochester, MN (P.J.D.); Alnylam Pharmaceuticals, Cambridge, MA (P.J.G., S.G., J.C., A.L.S., S.V.N., M.T.S., P.P.G., A.K.V., J.A.G.); and the Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden (O.B.S.).
Background: Patisiran, an investigational RNA interference therapeutic agent, specifically inhibits hepatic synthesis of transthyretin.
Methods: In this phase 3 trial, we randomly assigned patients with hereditary transthyretin amyloidosis with polyneuropathy, in a 2:1 ratio, to receive intravenous patisiran (0.3 mg per kilogram of body weight) or placebo once every 3 weeks.
Period-dependent Associations between Hypotension during and for Four Days after Noncardiac Surgery and a Composite of Myocardial Infarction and Death: A Substudy of the POISE-2 Trial.
Anesthesiology
February 2018
From the Departments of Outcomes Research (D.I.S., N.M.Z., G.M.) and Quantitative Health Sciences (N.M.Z., G.M.), Cleveland Clinic, Cleveland, Ohio; the Department of Anaesthesia and Intensive Care, Bispebjerg Hospital (C.S.M.) and the Department of Anaesthesiology, Herlev Hospital (C.S.M., R.M.D.), University of Copenhagen, Copenhagen, Denmark; the Department of Anaesthesia and Pain Management, Royal Melbourne Hospital, Melbourne, Australia (K.L.); the Department of Research, Grupo de Cardiología Preventiva Universidad Autónoma de Bucaramanga, Fundación CardioInfantil Instituto de Cardiología, Bucaramanga, Colombia (S.M.V.); the Anaesthetic Department, Hull and East Yorkshire Hospitals, National Health Service Trust, Hull, East Yorkshire, United Kingdom (P.B.); Department of Cardiology, Hospital de la Santa Creu i Sant Pau, IIB-SantPau, Universidad Autónoma de Barcelona, Barcelona (J.A.-G.); the Research Institute, Hospital do Coração, São Paulo, Brazil (A.B.C.); the Department of Anesthesia, Queen's University and Kingston General Hospital, Kingston, Canada (J.L.P.); Rahate Surgical Hospital, Nagpur, Maharashtra, India (P.V.R.); the Department of Anesthesia and Intensive Care Medicine, University Hospital Basel, University of Basel, Basel, Switzerland (M.D.S.); the Department of Vascular Surgery, Sapienza University of Rome, Rome, Italy (B.G.); Counties Manukau District Health, Aukland, New Zealand (S.A.W.); the Krishna Institute of Medical Sciences, Hyderbad, India (R.K.P.); the Department of Pediatrics, Hvidovre Hospital, Copenhagen, Denmark (R.M.D.); the Department of Anaesthetics, University of KwaZulu-Natal, Pietermaritzburg, South Africa (R.R.), the Hypertension and Vascular Aging Center, Hospital Universitario Austral, Pilar, Argentina (F.B.); the Departments of Health Research Methods, Evidence, and Impact and Medicine, McMaster University, Hamilton, Canada (P.J.D.); and the Population Health Research Institute, Hamilton, Canada (E.D., P.J.D., D.I.S.).
Background: The relative contributions of intraoperative and postoperative hypotension to perioperative morbidity remain unclear. We determined the association between hypotension and a composite of 30-day myocardial infarction and death over three periods: (1) intraoperative, (2) remaining day of surgery, and (3) during the initial four postoperative days.
Methods: This was a substudy of POISE-2, a 10,010-patient factorial-randomized trial of aspirin and clonidine for prevention of myocardial infarction.
Thyroid Function Within the Normal Range, Subclinical Hypothyroidism, and the Risk of Atrial Fibrillation.
Circulation
November 2017
Department of General Internal Medicine, Inselspital, Bern University Hospital, (C.B., M.F., C.F., D.A., N.R.)
Background: Atrial fibrillation (AF) is a highly prevalent disorder leading to heart failure, stroke, and death. Enhanced understanding of modifiable risk factors may yield opportunities for prevention. The risk of AF is increased in subclinical hyperthyroidism, but it is uncertain whether variations in thyroid function within the normal range or subclinical hypothyroidism are also associated with AF.
View Article and Find Full Text PDFImpact of Methylprednisolone on Postoperative Quality of Recovery and Delirium in the Steroids in Cardiac Surgery Trial: A Randomized, Double-blind, Placebo-controlled Substudy.
Anesthesiology
February 2017
From the Department of Surgery, University of Melbourne, Melbourne, Victoria, Australia (C.F.R., J.O.-Y., A.R.); Department of Anaesthesia and Pain Management (C.F.R.) and Department of Cardiothoracic Surgery (A.R.), The Royal Melbourne Hospital, Melbourne, Victoria, Australia; Department of Outcomes Research, Anesthesiology Institute, Cleveland Clinic, Cleveland, Ohio (L.S., A.K., A.A., K.P.D.I.S.); Department of Surgery (R.W., P.J.D.), Population Health Research Institute (R.W., J.V., P.J.D.), Hamilton Health Sciences and McMaster University, Hamilton, Ontario, Canada; and Department of Anesthesiology, Faculty of Medicine, Chiang Mai University, Thailand (K.P.).
Background: Inflammation after cardiopulmonary bypass may contribute to postoperative delirium and cognitive dysfunction. The authors evaluated the effect of high-dose methylprednisolone to suppress inflammation on the incidence of delirium and postoperative quality of recovery after cardiac surgery.
Methods: Five hundred fifty-five adults from three hospitals enrolled in the randomized, double-blind Steroids in Cardiac Surgery trial were randomly allocated to placebo or 250 mg methylprednisolone at induction and 250 mg methylprednisolone before cardiopulmonary bypass.
Withholding versus Continuing Angiotensin-converting Enzyme Inhibitors or Angiotensin II Receptor Blockers before Noncardiac Surgery: An Analysis of the Vascular events In noncardiac Surgery patIents cOhort evaluatioN Prospective Cohort.
Anesthesiology
January 2017
From the London Kidney Clinical Research Unit, London Health Sciences Centre, London, Ontario, Canada (P.S.R.); Departments of Medicine (B.R., A.P., O.S., E.D., E.P.B.-C., G.H.G., F.K.B., V.T., A.W., F.A.S., Z.P., P.J.D.), Clinical Epidemiology and Biostatistics (B.R., E.D., E.P.B.-C., G.H.G., Y.L.M., A.W., P.J.D.), and Anesthesiology (Y.L.M., J.P., K.E.R.), McMaster University, Hamilton, Ontario, Canada; Population Health Research Institute, Hamilton, Ontario, Canada (E.D., E.P.B.-C., Y.L.M., F.K.B., A.T., M.K., B.D., P.J.D.); Department of Outcomes Research, Cleveland Clinic, Cleveland, Ohio (D.I.S.); Department of Anesthesiology, University of Wisconsin, Madison, Wisconsin (R.D.S.); and Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada (E.N.S., E.E.M.).
Background: The effect on cardiovascular outcomes of withholding angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers in chronic users before noncardiac surgery is unknown.
Methods: In this international prospective cohort study, the authors analyzed data from 14,687 patients (including 4,802 angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker users) at least 45 yr old who had in-patient noncardiac surgery from 2007 to 2011. Using multivariable regression models, the authors studied the relationship between withholding angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers and a primary composite outcome of all-cause death, stroke, or myocardial injury after noncardiac surgery at 30 days, with intraoperative and postoperative clinically important hypotension as secondary outcomes.
Effect of Short-Term vs. Long-Term Blood Storage on Mortality after Transfusion.
N Engl J Med
November 2016
From the Departments of Medicine (N.M.H., D.M.A., Y.L., R.B., M.A.C., P.J.D., J.H., T.E.W., J.W.E.), Pathology and Molecular Medicine (N.M.H., M.A.C., T.E.W., K.E.W.), and Clinical Epidemiology and Biostatistics (N.M.H., P.J.D.) and McMaster Centre for Transfusion Research (N.M.H., R.J.C., D.M.A., Y.L., R.B., T.E.W., K.E.W.), McMaster University, Canadian Blood Services (N.M.H., D.M.A., K.E.W.), the Population Health Research Institute (P.J.D., J.W.E.), and the Thrombosis and Atherosclerosis Research Institute (J.W.E.), Hamilton, ON, and the Department of Statistics and Actuarial Science, University of Waterloo, Waterloo, ON (R.J.C.) - all in Canada; SA Pathology Transfusion Service, Flinders Medical Centre and Flinders University, Adelaide, SA, Australia (D.R., M.S.-T.); the Departments of General Anesthesiology (A.K.) and Outcomes Research (A.K., D.I.S.), Anesthesiology Institute, and the Robert J. Tomsich Pathology and Laboratory Medicine Institute and the Department of Laboratory Medicine (P.F.), Cleveland Clinic, Cleveland; and Meir Medical Center Kfar Saba and Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel (M.E.).
Background: Randomized, controlled trials have suggested that the transfusion of blood after prolonged storage does not increase the risk of adverse outcomes among patients, although most of these trials were restricted to high-risk populations and were not powered to detect small but clinically important differences in mortality. We sought to find out whether the duration of blood storage would have an effect on mortality after transfusion in a general population of hospitalized patients.
Methods: In this pragmatic, randomized, controlled trial conducted at six hospitals in four countries, we randomly assigned patients who required a red-cell transfusion to receive blood that had been stored for the shortest duration (short-term storage group) or the longest duration (long-term storage group) in a 1:2 ratio.
Five-Year Outcomes after Off-Pump or On-Pump Coronary-Artery Bypass Grafting.
N Engl J Med
December 2016
From the Population Health Research Institute, Hamilton Health Sciences, McMaster University, Hamilton, ON (A.L., P.J.D., R.P.W., Y.O., P.G., S.P., S.Y.), Centre Hospitalier de l'Université de Montréal, Montreal (N.N.), and the University of Calgary, Calgary, AB (R.J.N.) - all in Canada; the Center for Chronic Disease Control, Gurgaon (D.P.), SAL Hospital, Ahmedabad (A.R.J.), G. Kuppuswamy Naidu Memorial Hospital, Coimbatore (C.P.), and All India Institute of Medical Sciences, New Delhi (B.A.) - all in India; the University of Oxford, Oxford, United Kingdom (D.P.T.); Fu Wai Cardiovascular Hospital, Xicheng District, Beijing (S.H.), and Wuhan Asia Heart Hospital, Wuhan (L.T.) - both in China; Third Faculty of Medicine Charles University, University Hospital Kralovske Vinohrady, Prague, Czech Republic (Z.S.); Instituto Dante Pazzanese de Cardiologia, São Paulo (L.S.P., A.A.); Ankara University School of Medicine, Ankara, Turkey (A.R.A.); Hospital Regional de Temuco and Universidad de la Frontera, Temuco, Chile (F.L.Z., J.-C.B.); Fundación Médica de Río Negro y Neuquén, Rio Negro, Argentina (P.A.O.); and North Estonia Medical Center, Tallinn, Estonia (T.-A.S.).
Background: We previously reported that there was no significant difference at 30 days or at 1 year in the rate of the composite outcome of death, stroke, myocardial infarction, or renal failure between patients who underwent coronary-artery bypass grafting (CABG) performed with a beating-heart technique (off-pump) and those who underwent CABG performed with cardiopulmonary bypass (on-pump). We now report the results at 5 years (the end of the trial).
Methods: A total of 4752 patients (from 19 countries) who had coronary artery disease were randomly assigned to undergo off-pump or on-pump CABG.
Perioperative Aspirin for Prevention of Venous Thromboembolism: The PeriOperative ISchemia Evaluation-2 Trial and a Pooled Analysis of the Randomized Trials.
Anesthesiology
December 2016
From the Department of Medicine Hamilton, McMaster University, Hamilton, Ontario, Canada (J.W.E., C.K., G.G., S.Y., D.C., J. Douketis, A.P., E.D., P.J.D.); Departments of Outcomes Research and General Anesthesiology, Anesthesiology Institute, Cleveland Clinic, Cleveland, Ohio (D.I.S., A.K.); Department of Medicine Hamilton, St Joseph's Healthcare, Hamilton, Ontario, Canada (D.C., J. Douketis); Department of Anesthesiology, Queen's University and Kingston General Hospital, Kingston, Ontario, Canada (R.A.), Departments of Anesthesia and Perioperative Medicine and Epidemiology and Biostatistics, University of Western Ontario, London, Ontario, Canada (P.M.J.); Research Department, Fundaciòn Cardioinfantil, Bogotà, Colombia (R.J.D.); Department of Anaesthesia, University of Adelaide and Royal Adelaide Hospital, Adelaide, South Australia, Australia (T.W.P.); Departments of Anesthesiology and Neurological Surgery, The Ohio State University Wexner Medical Center, Columbus, Ohio (S.D.B.); Department of Anaesthesia and Pain Management, Royal Melbourne Hospital, Melbourne, Victoria, Australia (K.L.); Toronto General Hospital, Li Ka Shing Knowledge Institute of St. Michael's Hospital and Department of Anesthesia, University of Toronto, Toronto, Ontario, Canada (D.N.W.); Population Health Research Institute, Hamilton, Ontario, Canada (J.W.E., S.Y., K.B., E.D., S.M., J. Douketis, P.J.D.); Department of Anesthesia, Wake Forest School of Medicine, Winston-Salem, North Carolina (S.M.); and Department of Anaesthesiology, University of the Free State, Bloemfontein, South Africa (J. Diedericks).
Background: The PeriOperative ISchemia Evaluation-2 (POISE-2) trial compared aspirin with placebo after noncardiac surgery.
Methods: The authors randomly assigned 10,010 patients undergoing noncardiac surgery to receive 200 mg aspirin or placebo 2 to 4 h before surgery and then 100 mg aspirin daily or placebo daily for up to 30 days after surgery. Herein, the authors report the effect of aspirin on venous thromboembolism (VTE), including deep vein thrombosis and pulmonary embolism, as well as an updated pooled analysis of randomized trials of antiplatelet therapy for VTE prevention in noncardiac surgery patients.
Preoperative Score to Predict Postoperative Mortality (POSPOM): Derivation and Validation.
Anesthesiology
March 2016
From the Department of Anesthesia (Y.L.M.), Department of Clinical Epidemiology and Biostatistics (Y.L.M., P.J.D.), and Department of Medicine (P.J.D.), Faculty of Health Sciences, Michael DeGroote School of Medicine, McMaster University, Hamilton, Canada; Perioperative Research Group, Population Health Research Institute, Hamilton, Canada (Y.L.M., R.R.); Centre for Statistics in Medicine, Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom (G.C.); Perioperative Research Group, Department of Anaesthesia, University of KwaZulu-Natal, Pietermaritzburg, South Africa (R.R.); Department of Biostatistics and Medical Information, Necker University Hospital, Assistance Publique Hôpitaux de Paris, France (C.L.B.-B.); Perioperative Research Group, Department of Anaesthetics, Nelson R Mandela School of Medicine, University of KwaZulu-Natal, Pietermaritzburg, South Africa (B.B.); Department of Emergency Medicine and Surgery, CHU Pitié-Salpêtrière, Paris, France (B.R.); Population Health Research Institute, David Braley Cardiac, Vascular and Stroke Research Institute, Perioperative Medicine and Surgical Research Unit, Hamilton, Ontario, Canada (P.J.D.); and Montpellier 1 University, Faculty of Medicine, Department of Biostatistics, Clinical Research and Medical Informatics, Nîmes University Hospital, Nîmes, France (P.L.).
Background: An accurate risk score able to predict in-hospital mortality in patients undergoing surgery may improve both risk communication and clinical decision making. The aim of the study was to develop and validate a surgical risk score based solely on preoperative information, for predicting in-hospital mortality.
Methods: From January 1, 2010, to December 31, 2010, data related to all surgeries requiring anesthesia were collected from all centers (single hospital or hospitals group) in France performing more than 500 operations in the year on patients aged 18 yr or older (n = 5,507,834).
Nitrous Oxide and Serious Long-term Morbidity and Mortality in the Evaluation of Nitrous Oxide in the Gas Mixture for Anaesthesia (ENIGMA)-II Trial.
Anesthesiology
December 2015
From the Department of Anaesthesia and Pain Management, Royal Melbourne Hospital, and Anaesthesia, Perioperative and Pain Medicine Unit, and Department of Pharmacology and Therapeutics, University of Melbourne, and Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia (K.L.); Department of Anaesthesia and Perioperative Medicine, The Alfred Hospital, and Academic Board of Anaesthesia and Perioperative Medicine, and Department of Epidemiology and Preventive Medicine, Monash University, and National Health and Medical Research Council Practitioner Fellow, Melbourne, Australia (P.S.M.); Department of Epidemiology and Preventive Medicine (J.K., A.F.), Monash University, Melbourne, Australia; Department of Anaesthesia, Austin Hospital, and Department of Surgery, University of Melbourne, Melbourne, Australia (P.J.P.); Department of Anaesthesia, Chinese University of Hong Kong, Hong Kong Special Administrative Region, People's Republic of China (M.T.V.C.); Department of Anaesthesia and Pain Medicine, Royal Perth Hospital, Perth, Australia, and School of Medicine and Pharmacology, University of Western Australia, Perth, Western Australia, Australia (M.J.P.); Department of Outcomes Research, Cleveland Clinic, Cleveland, Ohio (D.I.S.); Department of Anesthesia, University of Toronto, and Department of Anaesthesia, Toronto General Hospital, Toronto, Ontario, Canada (W.S.B.); Population Health Research Institute, Hamilton Health Sciences and McMaster University, and Departments of Medicine, Clinical Epidemiology, and Biostatistics, McMaster University, Hamilton, Ontario, Canada (P.J.D.); and Department of Anaesthesia and Perioperative Medicine, Alfred Hospital, and Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia (S.W.).
Background: The Evaluation of Nitrous Oxide in the Gas Mixture for Anaesthesia (ENIGMA)-II trial randomly assigned 7,112 noncardiac surgery patients at risk of perioperative cardiovascular events to 70% N2O or 70% N2 groups. The aim of this follow-up study was to determine the effect of nitrous oxide on a composite primary outcome of death and major cardiovascular events at 1 yr after surgery.
Methods: One-year follow-up was conducted via a medical record review and telephone interview.
Methylprednisolone Does Not Reduce Persistent Pain after Cardiac Surgery.
Anesthesiology
December 2015
From the Department of Outcomes Research, Anesthesiology Institute, Cleveland Clinic, Cleveland, Ohio (A.T., D.I.S., J.-P.Y., V.N., S.A.); Departments of Clinical Epidemiology and Biostatistics (E.P.B.-C., P.J.D., A.L., R.P.W.) and Medicine (P.J.D., S.Y.), McMaster University, Hamilton, Ontario, Canada; Population Health Research Institute, Hamilton Health Sciences, McMaster University, Hamilton, Ontario, Canada (J.V., P.J.D., S.Y., A.L., R.P.W.); Department of Surgery, Population Health Research Institute, Hamilton Health Sciences, McMaster University, Hamilton, Ontario, Canada (R.v.O., G.C., A.L., R.P.W.); Department of Anesthesiology, West China Hospital, Sichuan University, Chengdu, China (H.Y.); Division of Cardiac Surgery, Department of Surgery, Dalhousie University, Halifax, Nova Scotia, Canada (J.-F.L.); Department of Surgery, Royal Melbourne Hospital, University of Melbourne, Melbourne, Australia (A. Royse); Department of Anesthesiology, Montreal Heart Institute, Université de Montréal, Montreal, Quebec, Canada (A. Rochon); and Department of Surgery, London Health Sciences Centre, London, Ontario, Canada (M.Q.).
Background: Persistent incisional pain is common after cardiac surgery and is believed to be in part related to inflammation and poorly controlled acute pain. Methylprednisolone is a corticosteroid with substantial antiinflammatory and analgesic properties and is thus likely to ameliorate persistent surgical pain. Therefore, the authors tested the primary hypothesis that patients randomized to methylprednisolone have less persistent incisional pain than those given placebo.
View Article and Find Full Text PDFOrbital osteoma: clinical features and management options.
Ophthalmic Plast Reconstr Surg
September 2014
*Department of Ophthalmology, Oculoplastic and Orbital Surgery Service, University of Colorado Denver, Denver, Colorado; †Department of Ophthalmology, Oculoplastic, Facial Cosmetic, and Orbital Surgery Service, University of Wisconsin-Madison, Madison, Wisconsin; ‡Department of Otolaryngology and Head and Neck Surgery, University of Colorado Denver, Denver, Colorado, U.S.A.; §Oculoplastics and Orbit Division, King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia; ‖Oculoplastics Division, Wilmer Eye Institute, Johns Hopkins University, Baltimore, Maryland, U.S.A.; On leave of absence from the ¶Craniofacial Unit of the Department of Ophthalmology, Otorhinolaryngology and Head and Neck Surgery, School of Medicine of Ribeirão Preto-University of São Paulo, São Paulo, Brazil; and #Department of Ophthalmology, Oculoplastics, Lacrimal, and Orbital Surgery Service, University of British Columbia, Vancouver, British Columbia, Canada.
Article Synopsis
- This study examined 11 cases of sino-orbital osteoma, focusing on their clinical presentation and management.
- The analysis included medical records, radiologic reports, and previous literature to provide a comprehensive overview of the cases, which had a mean follow-up time of 16 months and varied surgical approaches.
- The findings suggest that while osteomas are common in the paranasal sinuses, their occurrence in the orbit is rare, and successful outcomes can be achieved with both complete removal and partial sculpting based on individual cases.
Myocardial injury after noncardiac surgery: a large, international, prospective cohort study establishing diagnostic criteria, characteristics, predictors, and 30-day outcomes.
Anesthesiology
March 2014
From the Hamilton General Hospital, David Braley Cardiac, Vascular, and Stroke Research Institute, Population Health Research Institute, Hamilton, Ontario, Canada (P.J.D.); and Members of The VISION Writing Group and VISION Investigators, who are listed in appendix 1 and appendix 2, respectively. Population Health Research Institute, Hamilton, Ontario, Canada; Department of Clinical Research, Estudios Clinicos Latino America (ECLA), Rosario, Argentina Biomedical Research Institute Sant Pau (IIB Sant Pau), Barcelona, Spain The Chinese University of Hong Kong, Shatin, N.T., Hong Kong Universidad Autónoma de Bucaramanga and Fundación Cardioinfantil, Colombia St. John's Medical College and Research Institute, Bangalore, India Department of Surgery, University of Manitoba, Winnipeg, Manitoba, Canada Department of Clinical Epidemiology and Biostatistics and Department of Medicine, McMaster University, Hamilton, Ontario, Canada Hospital General Universitario Gregorio Maranon, Madrid, Spain University of Alberta, Edmonton, Alberta, Canada University of Malaya, Kuala Lampur, Malaysia Research Institute Hcor (Hospital do Coracao), Sao Paulo, Brazil Barts & The London School of Medicine and Dentistry, London, United Kingdom University of Kwazulu-Natal, Durban, South Africa Christian Medical College, Ludhiana, India Universidad PeruanaCayetano Heredia, Lima, Peru The George Institute for Global Health, University of Sydney, Sydney, Australia Population Health Research Institute, Hamilton, Ontario, Canada; University of Kwazulu-Natal, Durban, South Africa Department of Clinical Epidemiology and Biostatistics, and Department of Medicine, McMaster University, Hamilton, Ontario, Canada Hospital de Clinicas de Porto Alegre, Universidade Federal de Rio Grande do Sul, Brazil Jagiellonian University Medical College, Krakow, Poland The Cleveland Clinic, Cleveland, Ohio Population Health Research Institute, Hamilton, Ontario, Canada; Department of Medicine, McMaster University, Hamilto
Background: Myocardial injury after noncardiac surgery (MINS) was defined as prognostically relevant myocardial injury due to ischemia that occurs during or within 30 days after noncardiac surgery. The study's four objectives were to determine the diagnostic criteria, characteristics, predictors, and 30-day outcomes of MINS.
Methods: In this international, prospective cohort study of 15,065 patients aged 45 yr or older who underwent in-patient noncardiac surgery, troponin T was measured during the first 3 postoperative days.